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The principle of the molecular organization of adhe-
rens junctions follows a uniform pattern, which is
found in epithelial, muscular, neuroneal as well as in
endothelial cells and is highly conserved among
species. Transmembrane molecules of the cadherin
family link to catenins, which anchor the adhesion
plaque to the cytoskeleton. The kind of cadherin
used in adherens junctions is cell-type speci®c,
vascular endothelial (VE)-cadherin is speci®c for
endothelial cells. The assembly and disassembly of
the cadherin/catenin complex is dynamic and regu-
lated by growth factors. The functional status of
adherens junctions controls endothelial cell-to-cell
adhesion, cell scattering, vessel morphogenesis and
has intracellular signaling properties, thereby playing
an important role in vasculogenesis and angiogenesis.
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MOLECULES INVOLVED IN THE FORMATION OF
VASCULAR ADHERENS JUNCTIONS
Cell adhesion is crucial for the assembly of cells into three
dimensional tissues. One of the most important and ubiquitous
types of adhesive interaction between cells is mediated by
cadherins. Cadherins are transmembrane, Ca2+-dependent recep-
tors, which after dimerization and clustering form antiparallel
homotypic adhesive complexes with neighboring cells (Steinberg
and McNutt, 1999). Many studies found a correlation between
cadherin expression or function and the formation of tissue
boundaries, tissue rearrangement, cell migration, cell differenti-
ation, and metastasis (Tepass, 1999). Many tissue-speci®c cadherins
have been identi®ed, including epithelial (E)-cadherin, neuroneal
(N)-cadherin, placental (P)-cadherin, vascular endothelial (VE)-
cadherin, and others. The disturbed expression or function of such
individual cadherins results in abnormal development of the
respective organs (Larue et al, 1994; Radice et al, 1997; Vittet
et al, 1997; Carmeliet et al, 1999).
Although the ectodomain of cadherins is suf®cient to mediate
cell aggregation, it is the cytodomain of cadherins, which contains
several functional elements, that allows cadherin-dependent cell-to-
cell adhesion to be regulated. The membrane proximal cytoplasmic
region of cadherins binds to the catenin p120ctn (formerly called
p120CAS). Depending on the state of p120ctn, this molecule can
enhance or inhibit cadherin-mediated cell adhesion (Aono et al,
1999). Adjacent and distal to the p120ctn binding site, the
cytodomain of cadherins interacts with b-catenin or g-catenin
(also called plakoglobin). These two catenins bind to a-catenin,
which is an actin-binding and actin-bundling molecule linking the
adhesive cadherin/catenin complex to the F-actin-based cyto-
skeleton (Provost and Rimm, 1999). Other binding partners of
a-catenin are vinculin, a-actinin, ZO-1, and possibly spectrin.
The protein complex between cadherins, catenins, and F-actin
shapes the so-called adherens junction. The principle architecture
of such junctions is preserved among species and comparable even
between invertebrates and vertebrates. The type of cadherin found
in the respective species and tissue is speci®c and determines tissue-
speci®c morphogenesis and functions. The unique cadherin found
in adherens junctions of human endothelial cells is vascular
endothelial (VE)-cadherin (Breviario et al, 1995; Dejana, 1997).
Endothelial cells express two other cadherins, vascular endothelial
(VE)-cadherin-2 and N-cadherin (Salomon et al, 1992; Telo¢ et al,
1998), but these two cadherins do not participate in endothelial
adherens junction formation and do not anchor to the cytoskeleton.
VE-cadherin merges into adherens junctions as early as 2 h after
seeding of endothelial cells onto tissue culture plastic. Then VE-
cadherin forms multiple lateral patches that develop into an
extensive belt-like structure over a period of 24 h (Fig 1).
Interestingly, light and electron microscopic studies in endothelial
cells have shown that also another cell-to-cell adhesion molecule
called platelet endothelial cell adhesion molecule-1 (PECAM-1;
CD31) becomes progressively associated with adherens junctions
(Leach et al, 1993; Ayalon et al, 1994). Moreover, like VE-
cadherin, PECAM-1 also physically interacts with b-catenin and
thus participates in shaping the endothelial adherens junction (Ilan
et al, 1999; Matsumura et al, 1997).1
ADHERENS JUNCTION FUNCTION
In angiogenesis The importance of VE-cadherin for vessel
formation is emphasized by the fact that a VE-cadherin knockout
mouse is unable to form vascular structures and dies around day 10
during embryonic development (Carmeliet et al, 1999). Using
endothelium in cell culture it was possible to show that VE-
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cadherin allows capillary tube formation and the maintenance of a
single cell layered investment of vascular lumens (Matsumura et al,
1997; Vittet et al, 1997; Bach et al, 1998a; Halama et al, 1999).
Saturation of VE-cadherin-dependent cell-to-cell contacts mediates
growth stop at con¯uence (Caveda et al, 1996; Halama et al, 1999).
Interestingly, VE-cadherin also allows endothelial cells to interact
with ®brin and this interaction also induces the formation of
capillary tubes in vitro (Bach et al, 1998a, b).
By contrast, a PECAM-1 knockout animal has no apparent
vascular malformation (Duncan et al, 1999), indicating that
functions of PECAM-1 during vessel formation can be fully
compensated by other molecules, most likely by VE-cadherin itself.
Moreover, PECAM-1 alone in the absence of VE-cadherin is not
able to confer growth stop signals after reaching con¯uence and
such cells do not form capillary tubes in vitro (Halama et al, 1999).
The function of PECAM-1 in adherens junctions only becomes
apparent when basic ®broblast growth factor (FGF)-stimulated
endothelial cells are analyzed. PECAM-1 reduces FGF-induced
polarization of the F-actin network towards the protruding edges of
the cell and reduces FGF-induced cell scattering. Moreover,
following FGF withdrawal, PECAM-1 accelerates F-actin realign-
ment into parallel bundles and restoration of an intact monolayer.1
These effects can be attributed to the fact that PECAM-1 reduces
FGF-induced dissociation of VE-cadherin complexes and enhances
their reformation after FGF withdrawal. Although the basis of this
effect is still unclear, it is most likely mediated indirectly, because
PECAM-1 and VE-cadherin do not physically interact. The
cytoplasmic tails of PECAM-1 and VE-cadherin have no
homology, thus they probably use a distinct region on b-catenin
for binding.
Signals regulating the stability of the VE-cadherin/catenin
complexes are only partially understood, and it appears that
protein-tyrosine phosphatases such as PTPmu, PTP-1B, or LAR-
PTP are involved, which associate with the VE-cadherin/b-catenin
complex and thereby increase the cohesivity of the complex (Kypta
et al, 1996; Balsamo et al, 1998; Brady-Kalnay et al, 1998; Ozawa
and Kemler, 1998; Muller et al, 1999). Also PECAM-1 can
associate with protein-tyrosine phosphatases via its src homology 2
domain binding motif (Hua et al, 1998; Jackson et al, 1997;
Newton-Nash and Newman, 1999), which may be the mechanism
by which PECAM-1 enhances the stability of the cadherin/catenin
complex.
Taken together these data emphasize the tight regulation of the
assembly of the adherens junction complex. VE-cadherin and
PECAM-1 in conjunction control the maintenance of a stable
vascular tree. VE-cadherin appears to be required to allow
endothelial cells to respond to growth factor stimulation, as
evidenced by the fact that transfectants expressing PECAM-1 only,
but not VE-cadherin do not respond to growth factors (Fig 2). In
this respect PECAM-1 appears to stabilize the junctional complex
against FGF-induced dissociation, because in cells coexpressing
VE-cadherin and PECAM-1, junction dissociation is limited to a
short transient peak resulting in an accelerated reformation of a
tight endothelial monolayer.1
In leukocyte transmigration The VE-cadherin knockout
mouse cannot be used to assess the function of VE-cadherin during
leukocyte migration, because these mice die during embryonic
development; however, from several in vitro experiments it is well
documented that the adhesiveness of the adherens junction
complex controls permeability for macromolecules as well as for
emigrating leukocytes (Allport et al, 1997, 2000; Sandig et al, 1997;
Hordijk et al, 1999; Johnson-Leger et al 2000). It was thought that
neutrophils dissociate the adherens junction complex, thereby
altering the permeability of the vascular wall for permeating cells
(Allport et al, 1997); however, other studies suggested that this
phenomenon might re¯ect degradation by neutrophil proteases
released during specimen preparation, thus being a cell culture
artifact (Moll et al, 1998). Still the fact remained that transmigrating
cells have to somehow cross the adherens junction barrier. Recent
Figure 1.Three color immuno¯uorescent
staining of endothelial cells grown as mono-
layers on tissue culture plastic. Laser scan
image, scale bar: 10 mm. Actin ®bers are stretched
from one cell border to the other and form a
delicate network of parallel-bundled ®bers. VE-
cadherin (cad-5) and b-catenin (B-CAT) colocal-
ize at the cell border forming an interdigitated and
belt-like junction zone between cells.
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studies employing monocytes were able to con®rm that a transient
and focal disruption of the VE-cadherin complex occurs during
leukocyte transmigration, which was inhibited by antibodies
(Allport et al 2000). Moreover, studies using FGF-stimulated
endothelium found that FGF signi®cantly enhanced transmigration
of mononuclear cells in dependence of the ability of FGF to
dissociate the cadherin/catenin complex,1 which con®rms the
concept that transmigration of cells is regulated by altering the
composition of the adherens junction complex.
The situation is different with regard to PECAM-1. In the
PECAM-1 knockout mouse transmigrating leukocytes were
trapped within the basement membrane documenting the role of
PECAM-1 during transmigration in an in vivo model (Duncan et al,
1999). Several in vitro experiments were able to con®rm this effect
of PECAM-1. PECAM-1 appears to function by providing a
``track'' for transmigrating cells between adjacent endothelial cells
(Berman and Muller, 1995; Piali et al, 1995; Poggi et al, 1996;
Prager et al, 1996; Pellegatta et al, 1998). Interestingly, employing
transfectants expressing PECAM-1 or VE-cadherin or both
molecules, the augmented transmigration of leukocytes in response
to FGF seen in cells coexpressing VE-cadherin and PECAM-1 was
not observed in cells expressing PECAM-1 only.1 These experi-
ments illustrate that PECAM-1-dependent mechanisms of directing
leukocytes through junctions are controlled by VE-cadherin in a
way sensitive to FGF.
In signaling It was initially thought that proteins of the adherens
junction complex are cell-to-cell adhesion molecules.
Subsequently, it was shown that b-catenin is not only involved
in modifying cadherin-based cell adhesion, but is also able to
transduce signals into the nucleus. This information mainly came
from investigations of the Drosophila protein armadillo and
the Xenopus b-catenin, which are both homolog to the human
b-catenin. Armadillo and Xenopus b-catenin were found to be a
central part of the Wnt signaling pathway. Wnt proteins bind to
receptors of the Frizzled family and through several cytoplasmic
relay components (recently reviewed by Behrens, 2000), the signal
is transduced to b-catenin, which then enters the nucleus and forms
a complex with the Lef/tcf family of transcription factors and
activates transcription of Wnt target genes. A detailed description of
the Wnt pathway can be found on the Wnt gene homepage
HTTP://www.stanford.edu/~rnusse/wntwindow.html. This path-
way has also been described to function in human cells. Currently
known target genes activated by this pathway in human cells are
C-myc, cyclin D, Tcf-1, matrix metalloproteinase MMP-7, per-
oxisomal proliferator-activated receptor (PPARdelta), urokinase-
type plasminogen activator receptor (uPAR), c-jun, and fra-1 (He
et al, 1998, 1999; Brabletz et al, 1999; Mann et al, 1999; Shtutman et al,
1999; Tetsu and McCormick, 1999). In primary endothelial cells,
transfection with an expression vector for Wnt-1 increased the free
pool of b-catenin and the transcription of a Lef/tcf dependent
reporter gene construct and also induced proliferation of endothelial
cells in cell culture (Wright et al, 1999).
The source of transactivation-competent b-catenin is still under
debate: b-catenin is found in the cytosol in a complex with the
protein kinase GSK-3b, the adenomatosis polyposis coli protein
APC and Axin (Behrens et al, 1998; Behrens, 2000). It is well
documented that upon Wnt signaling, b-catenin is released from
this cytosolic complex and translocated into the nucleus. In
addition, as described above, b-catenin is linked to the cell
membrane in a complex with VE-cadherin and PECAM-1. Upon
stimulation with growth factors, such as epithelial growth factor
(EGF), FGF and others, this membrane-associated complex is
dissociated; however, it has yet not been directly proven that
membrane-derived b-catenin is indeed transactivation competent.
The existence of such a second pool of transactivation-competent
b-catenin is supported by the ®nding that the ectopic expression of
high amounts of cadherins antagonizes the signaling properties of
b-catenin (Fagotto et al, 1996; Torres et al, 1996; Orsulic et al,
1999). Moreover, in endothelial cells, FGF rapidly dissociates the
VE-cadherin/b-catenin complex and translocates b-catenin into
the nucleus.1 As described above, this effect of FGF is attenuated by
PECAM-1: PECAM-1 retains b-catenin within the junctional
adhesion complex and reduces the FGF-induced cadherin/catenin
dissociation and nuclear translocation of b-catenin to a short
transient peak.1 The functional consequences of nuclear transloc-
ation of b-catenin in the developed vascular tree are poorly
characterized. By analogy to the function of b-catenin in
Drosophila and Xenopus, it can be assumed that the liberation of
transactivation-competent b-catenin from the adherens junction
complex interferes with endothelial cell cycling, migration, and
vessel formation. Thus, the adherens junction complex offers itself
as a potential target for pro- and antiangiogenic treatment concepts.
CONCLUSION
The endothelial adherens junction complex controls cell morpho-
logy, organ shaping, and cell cycling. In the adult vascular tree the
maintenance of a quiescent endothelial cell monolayer appears to
depend on growth stop signals transmitted through VE-cadherin/
b-catenin, which is further supported by the observation that
mutations of b-catenin or deletion of cadherin is associated with
cancer (Polakis, 1999). Under physiologic conditions, growth
factors can temporarily and reversibly override this growth stop
signal provided by cadherin/b-catenin in order to allow new vessel
formation.
Figure 2.Transmission microscopy of ECV304 cells, stable trans-
fected with VE-cadherin, PECAM-1. or vector alone. Halama et al
(1999). Cells were cultured in RPMI/10% fetal calf serum (A, B, C) or in
RPMI/10% fetal calf serum/20 ng basic FGF. Whereas in the absence of
exogenous growth factors, both VE-cadherin- and PECAM-1-transfectants
cluster, FGF induces cell scattering in VE-cadherin, but not in the
PECAM-1 transfectants. Vector only cells scatter, whether FGF is present
or not.
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